生物制药企业ADC Therapeutics SA近日披露最新财务数据，截至2026年3月31日，公司持有的现金及现金等价物规模达2.31亿美元。根据当前资金消耗速率测算，该资金储备预计可维持公司运营至2028年。
这一财务指标显著增强了市场对该公司研发持续性的信心。作为专注于抗体偶联药物（ADC）开发的创新药企，充足的现金流将保障其核心管线推进及临床研究扩展。值得注意的是，资金续航能力至2028年的预测，为潜在合作伙伴及投资者提供了明确的战略规划窗口。
在生物科技行业融资环境充满挑战的背景下，ADC Therapeutics SA凭借稳健的财务状况展现出差异化优势。公司管理层表示，现有资金将优先用于加速关键临床项目，同时探索商业合作机会以最大化资产价值。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.